{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:39:10Z","timestamp":1759941550142,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41582-021-00558-w","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T16:31:53Z","timestamp":1630427513000},"page":"599-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biomarkers show value of studying dementia in Down syndrome"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-7599","authenticated-orcid":false,"given":"Ann-Charlotte","family":"Granholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Ledreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamaneurol.2018.3443","volume":"76","author":"MS Rafii","year":"2019","unstructured":"Rafii, M. S. & Santoro, S. L. Prevalence and severity of Alzheimer disease in individuals with Down syndrome. JAMA Neurol. 76, 142\u2013143 (2019).","journal-title":"JAMA Neurol."},{"key":"558_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jalz.2014.10.007","volume":"11","author":"D Hartley","year":"2015","unstructured":"Hartley, D. et al. Down syndrome and Alzheimer\u2019s disease: Common pathways, common goals. Alzheimers Dement. 11, 700\u2013709 (2015).","journal-title":"Alzheimers Dement."},{"key":"558_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/jir.12390","volume":"61","author":"M McCarron","year":"2017","unstructured":"McCarron, M. et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J. Intellect. Disabil. Res. 61, 843\u2013852 (2017).","journal-title":"J. Intellect. Disabil. Res."},{"key":"558_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(21)00139-3","volume":"20","author":"AM Fagan","year":"2021","unstructured":"Fagan, A. M. et al. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer\u2019s disease: a cross-sectional study. Lancet Neurol. 20, 615\u2013626 (2021).","journal-title":"Lancet Neurol."},{"key":"558_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jalz.2017.06.2268","volume":"14","author":"KM Kinnunen","year":"2018","unstructured":"Kinnunen, K. M. et al. Presymptomatic atrophy in autosomal dominant Alzheimer\u2019s disease: A serial magnetic resonance imaging study. Alzheimers Dement. 14, 43\u201353 (2018).","journal-title":"Alzheimers Dement."},{"key":"558_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2017.04.006","volume":"56","author":"JH Cole","year":"2017","unstructured":"Cole, J. H. et al. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiol. Aging 56, 41\u201349 (2017).","journal-title":"Neurobiol. Aging"},{"key":"558_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/genes12020268","volume":"12","author":"M Ferrari","year":"2021","unstructured":"Ferrari, M. & Stagi, S. Autoimmunity and genetic syndromes: A focus on Down syndrome. Genes 12, 268 (2021).","journal-title":"Genes"},{"key":"558_CR8","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson, A. R. et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 143, 1975\u20131998 (2020).","journal-title":"Brain"},{"key":"558_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(21)00129-0","volume":"20","author":"M Carmona-Iragui","year":"2021","unstructured":"Carmona-Iragui, M. et al. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurol. 20, 605\u2013614 (2021).","journal-title":"Lancet Neurol."},{"key":"558_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26178","author":"V Montal","year":"2021","unstructured":"Montal, V. et al. Metabolite signature of Alzheimer\u2019s disease in adults with Down syndrome. Ann. Neurol. https:\/\/doi.org\/10.1002\/ana.26178 (2021).","journal-title":"Ann. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00558-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00558-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00558-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T13:31:41Z","timestamp":1632835901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00558-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1038\/s41582-021-00558-w","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"type":"print","value":"1759-4758"},{"type":"electronic","value":"1759-4766"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"31 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}